TrianglePaclitaxel Q2W (NCT07795749)
Paclitaxel Q2W trial for Esophageal Carcinoma (NCT07795749). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with selected digestive-tract adenocarcinomas spreading to the abdominal lining. The gastric or gastroesophageal group requires later recurrence after gastric-cancer surgery.
The idea: paclitaxel, which disrupts cell division, is delivered into the abdominal cavity alongside systemic therapy. Groups use two-week or three-week schedules. Researchers assess whether patients complete two treatment cycles. Eligibility depends on tumor type, prior abdominal treatments, and whether safe laparoscopy and port placement are possible.
This phase 2 study plans 55 patients. Maheswari Senthil leads at UC Irvine in Orange, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.